|
Match
|
Document |
Document Title |
|
|
6733763 |
Induction of cytotoxic T-lymphocyte responses
Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the...
|
|
|
6723329 |
Use of parapox B2L protein to modify immune responses to administered antigens
The Parapox B2L virus envelope protein is used as an adjuvant to enhance a subject's response to an administered antigen. Both antibody and cellular immune responses can be modified. B2L protein is...
|
|
|
6723327 |
Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
Methods for the prevention and treatment of disorders, including disorders of the skin and respiratory system, such as infection with mycobacteria such as M. tuberculosis or M. avium ,...
|
|
|
6722062 |
Capsular polysaccharides from enterococci
The present invention is directed to a method for purifying polysaccharides capable of inducing the production of high titers of opsonic antibodies that kill strains of enterococcal bacteria. In...
|
|
|
6719981 |
Stable, attenuated rabies virus mutants and live vaccines thereof
The present invention relates to recombinant rabies virus mutants comprising a mutation in the viral genome, whereby said mutation comprises at least a substitution of the Arg 333 codon in the...
|
|
|
6720182 |
Alternative splice variants of CD40
The invention concerns novel nucleic acid sequences and amino acid sequences obtained by alternative splicing, expression vectors, host cell and pharmaceutical compositions comprising said sequences.
|
|
|
6719984 |
Composition and method for immunomodulation in mammals
This invention relates to compositions and processes utilized to modulate the immune system of mammals. More particularly, the present invention relates to the use of low molecular weight...
|
|
|
6716434 |
Composition and method for immunostimulation in non- mammalian vertebrates
This invention relates to compositions utilized to modulate the immune system of non-mammalian vertebrates. More particularly, the present invention relates to the use of low molecular weight...
|
|
|
6716432 |
Pneumolysin mutants and pneumococcal vaccines made therefrom
Mutants of pneumolysin that are non-toxic by reason of amino acid substitutions have been constructed. These mutants elicit an immune response in animals that is reactive to wild-type pneumolysin....
|
|
|
6716422 |
Vaccine adjuvants for immunotherapy of melanoma
The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side...
|
|
|
6706266 |
Oncostatin M antagonists
The present invention relates to the use of an antagonist of OSM such as an antibody or small molecule in the manufacture of a medicament for the treatment or prophylaxis of an inflammatory...
|
|
|
6696061 |
Immunomodulatory peptides
A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues...
|
|
|
6692753 |
Potentiation of the immune response
A method for stimulating proliferation of T-cells containing cytoplasmic post-prolyl dipeptidase activity; the method, in one aspect, involves contacting the T-cells with an organic compound at a...
|
|
|
6689364 |
Borrelia burgdorferi polypeptides and uses thereof
The present invention provides novel polypeptides which are substantially free of a B. burgdorferi spirochete or fragments thereof and which are thus useful in compositions and methods for the...
|
|
|
6689370 |
Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
A therapeutic composition comprising (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence and (ii) at least one adjuvant comprising at least...
|
|
|
6685936 |
Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of suppressor T cells effective to reduce or inhibit host rejection of the...
|
|
|
6685933 |
Interferon α hybrids
Hybrid human interferon-α polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these peptides, and the use of these polypeptides to...
|
|
|
6682746 |
Adjuvanted vaccine which is substantially free of non-host albumin
Disclosed herein is a serum-based adjuvanted vaccine which is substantially free of non-host albumin and the use thereof in reducing or preventing post-vaccination systemic reactions.
|
|
|
6682731 |
Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.
|
|
|
6682740 |
Peptides derived fram complement peptide C3a sequence and antiallergic compositions comprising them
Peptides corresponding partially or entirely to positions 50-77 of the sequence of the complement-derived peptide C3 a and analogs thereof are capable of inhibiting IgE-mediated triggering and/or...
|
|
|
6676950 |
Neurokinin receptor antagonists and methods of use thereof for inhibiting HIV infection
Compositions and methods are provided which may be used to advantage for the treatment of HIV infection. More specifically, neurokinin receptor antagonists and methods for administration to inhibit...
|
|
|
6677302 |
Compositions and methods for the treatment of viral disorders
This invention relates to compositions and methods for the treatment of virus infections and other viral-associated disorders. Compositions comprise an inducing agent and an anti-viral agent. The...
|
|
|
6673609 |
Recombinant human erythropoietin with advantageous glycosylation profile
A method for the production of a polypeptide, the method comprising culturing, under conditions which allow for the expression of DNA encoding SEQ ID NO:2 in an eukaryotic host cell, wherein the...
|
|
|
6669947 |
Stratified and cryogenically stored vaccines, process for their preparation
A composition comprising at least one antigenic medium and at least one adjuvant, wherein the at least one antigenic medium and the at least one adjuvant each comprise one or more phases which are...
|
|
|
6670329 |
Selenocosmia huwena toxin and analgesic uses thereof
Disclosed is a analgesic composition containing the purified HWAP-I polypeptide of the Chinese bird spider, Selenocosmia Huwena.
|
|
|
6667025 |
Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
The methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression...
|
|
|
6667295 |
DNA vaccine against feline immunodeficiency virus
The present invention is directed to vaccine compositions that can be used to protect cats against feline immunodeficiency virus. More particularly, the present invention relates to polynucleotide...
|
|
|
6667037 |
Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
The invention relates to peptides which bind to HLA-B35 molecules, leading to recognition and lysis of the resulting complexes by cytolytic T cells. Also a part of the invention are nucleic acid...
|
|
|
6663873 |
Antigenic preparation for treatment or prevention of helicobacter infection
An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the lipopolysaccharide (LPS) of Helicobacter bacteria, particularly the LPS...
|
|
|
6663859 |
Compositions for enhancing the immune response
D-Ribose and methods for using D-Ribose are provided for enhancing the immune response in mammals. Those with a less than optimal immune response will benefit from oral or parenteral administration...
|
|
|
6660272 |
Porcine circoviruses, vaccines and diagnostic reagents
The invention relates to new porcine circovirus strains isolated from pulmonary or ganglionic samples obtained from farms affected by the post-weaning multisystemic wasting syndrome (PMWS). It...
|
|
|
6656481 |
Vaccinal preparations
Vaccinal preparations comprising an antigen such as tumor-associated antigens and viral antigens, together with a hydrophobized polysaccharide as adjuvant, e.g., hydrophobized polysaccharides...
|
|
|
6652861 |
Anti-HIV and anti-tumor peptides and truncated polypeptides of MAP30
Truncated MAP30 or GAP31 proteins retain anti-tumor and anti-viral activity but not the cytotoxic ribosome inactivation activity. These proteins also inhibit HIV without affecting fertility of sperm.
|
|
|
6649170 |
Adjuvant combinations for immunization composition and vaccines
A kit useful for immunization is described. The kit contains an antigenic substance from a Mycobacterium and an adjuvant combination of dimethyl dioctadecyl ammonium bromide and monophosphoryl...
|
|
|
6649172 |
Amphipathic aldehydes and their uses as adjuvants and immunoeffectors
This invention relates to novel aldehyde containing compounds and their uses as adjuvants and immunoeffectors.
|
|
|
6645495 |
Compositions of saponin adjuvants and excipients
Certain novel compositions of the adjuvant saponin QS-21 having improved properties are disclosed. The compositions of the present invention are designed (1) to minimize the lytic effects of QS-21,...
|
|
|
6645504 |
Bystander suppression of type I diabetes by oral administration of glucagon
Described are methods for treating or preventing type I diabetes and insulitis by oral administration of the bystander antigen glucagon. The methods involve oral administration of glucagon in an...
|
|
|
6635261 |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
The invention pertains to adjuvant and vaccine compositions of monophosphoryl lipid A, sugar and optionally an amine based surfactant, which when frozen and thawed or lyophilized and reconstituted...
|
|
|
6635253 |
Composition for enhancing immunological effects
An object of the present invention is to provide a composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, containing a stable...
|
|
|
6632439 |
Fusobacterium necrophorum vaccine and method for making such vaccine
The present invention relates to a method of producing a vaccine for the prevention of F. necrophorum bacterial infections, comprising isolating the F. necrophorum bacteria from a bovine...
|
|
|
6632793 |
Immunological activity for a peptide of the limulus anti-LPS factor
The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) Induce an antiviral state in both the Hep-2 and...
|
|
|
6632789 |
Methods for modulating T cell responses by manipulating intracellular signal transduction
Methods for modulating T cell responses by manipulating intracellular signals associated with T cell costimulation are disclosed. The methods involve inhibiting or stimulating the production of at...
|
|
|
6630146 |
Candida albicans phosphomannan complex as a vaccine
A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans . The composition includes phosphomannan of C. albicans...
|
|
|
6623740 |
Structurally modified peptides that are resistant to peptidase degradation
Human melanoma cells bear antigens that are recognized by autologous CD8 + cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by...
|
|
|
6620414 |
Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
A vaccine formulation for the treatment or prophylaxis of hepatitis, especially hepatitis B, infections is provided comprising the hepatitis antigen and a suitable carrier such as alum in...
|
|
|
6620416 |
Method for treating HIV
The present invention relates to peptides of one or more portions of the human chorionic gonadotropin β-chain as well as methods for treatment and prevention of diseases, including HIV infection,...
|
|
|
6613332 |
Oral administration of therapeutic proteins
An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and...
|
|
|
6610304 |
Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
The incorporation of multiple branch peptide constructions having activity against HIV into liposomes of sufficient size for white blood cell internalization (e.g. greater than 150 nm and...
|
|
|
6610308 |
Immunostimulant emulsion
The invention concerns an oil-in-water immunostimulant emulsion comprising an aqueous phase and an oil phase, characterised in that it further comprises an immunostimulant polynucleotide whereof at...
|
|
|
6610310 |
Polyanionic polymers as adjuvants for mucosal immunization
Mucosal adjuvants for vaccines contain water-soluble polyanionic polymers which have anionic constitutional units obtained from acids such as acrylic acid, methacrylic acid, maleic acid, fumaric...
|